1 week Ago By Defense World Staff
Norges Bank acquired a new position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 118,900 shares of the company’s stock, valued at approximately $9,151,000.
Norges Bank owned approximately 0.64% of Praxis Precision Medicines at the end of the most recent reporting period. A number of other institutional investors have also modified their holdings of the stock.
Vanguard Group Inc. raised its stake in Praxis Precision Medicines by 2.4% during the fourth quarter.
Vanguard Group Inc. now owns 1,063,639 shares of the company’s stock valued at $81,858,000 after buying an additional 24,645 shares in the last quarter. Assenagon Asset Management S.
A. increased its stake in Praxis Precision Medicines by 5,437.7% during the fourth quarter.
Assenagon Asset Management S.A. now owns 559,082 shares of the company’s stock valued at $43,027,000 after purchasing an additional 548,986 shares during the last quarter.
Franklin Resources Inc. increased its stake in Praxis Precision Medicines by 85.6% during the third quarter.
Franklin Resources Inc. now owns 445,233 shares of the company’s stock valued at $25,619,000 after purchasing an additional 205,335 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Praxis Precision Medicines by 1.
0% in the 3rd quarter. Geode Capital Management LLC now owns 398,838 shares of the company’s stock worth $22,954,000 after buying an additional 3,779 shares during the last quarter. Finally, CIBC Asset Management Inc grew its position in shares of Praxis Precision Medicines by 47.
3% during the 4th quarter. CIBC Asset Management Inc now owns 366,756 shares of the company’s stock valued at $28,226,000 after buying an additional 117,817 shares during the last quarter. Institutional investors and hedge funds own 67.
84% of the company’s stock. Praxis Precision Medicines Stock PerformanceShares of NASDAQ:PRAX opened at $28.60 on Wednesday.
The company has a market capitalization of $576.66 million, a PE ratio of -2.78 and a beta of 2.
66. The stock has a fifty day moving average of $54.74 and a 200-day moving average of $65.
89. Praxis Precision Medicines, Inc. has a one year low of $28.
33 and a one year high of $91.83. Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its quarterly earnings results on Friday, February 28th.
The company reported ($2.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.76) by ($0.
18). The company had revenue of $7.48 million during the quarter, compared to analyst estimates of $0.
36 million. Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.
86%. As a group, research analysts forecast that Praxis Precision Medicines, Inc. will post -10.
22 EPS for the current fiscal year. Analyst Ratings ChangesPRAX has been the subject of a number of analyst reports. Truist Financial reduced their price objective on Praxis Precision Medicines from $175.
00 to $85.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Needham & Company LLC reissued a “buy” rating and set a $85.
00 target price on shares of Praxis Precision Medicines in a research note on Tuesday. Robert W. Baird decreased their target price on shares of Praxis Precision Medicines from $117.
00 to $73.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd. Wedbush downgraded Praxis Precision Medicines from a “hold” rating to a “strong sell” rating in a research report on Friday, February 28th.
Finally, Deutsche Bank Aktiengesellschaft started coverage on Praxis Precision Medicines in a research report on Tuesday, February 11th. They issued a “buy” rating and a $111.00 target price on the stock.
One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $123.33.
View Our Latest Report on PRAXPraxis Precision Medicines Company Profile (Free Report)Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.See AlsoFive stocks we like better than Praxis Precision MedicinesTop Stocks Investing in 5G TechnologyTariff-Proof Stocks: 3 Big Bargains With Huge Upside PotentialGrowth Stocks: What They Are, What They Are NotQualcomm Breaks Down But RSI Signals It’s Severely Oversold3 Small Caps With Big Return PotentialTesla’s #1 Bull Cuts Target But Says It’s Still a BuyWant to see what other hedge funds are holding PRAX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report)..
